GSK

News

GSK ends decades-long hiatus in oral antibiotics for UTIs

The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.

News

GSK taps into UK health data for dementia study

GSK joins with two UK research organisations to explore a possible link between its shingles vaccine Shingrix and a reduced risk of dementia.

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

News

FDA sets June date for Gilead's twice-yearly HIV PrEP

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

Vaccines production line at GSK facility in Wavre, Belgium

GSK gets ready for its next big vaccine launch

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

GSK ends decades-long hiatus in oral antibiotics for UTIs

GSK taps into UK health data for dementia study

GSK bows to Trump pressure and pauses diversity policies

FDA sets June date for Gilead's twice-yearly HIV PrEP

GSK gets ready for its next big vaccine launch

GSK rides out vaccine sales weakness with cancer, HIV gains

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

GSK

Editor's Picks